Welcome to our dedicated page for Mannkind SEC filings (Ticker: MNKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MannKind Corporation filings document formal disclosures for a Nasdaq-listed biopharmaceutical company focused on inhaled and drug-device therapies. Its 8-K reports furnish operating results and business updates for Afrezza, Furoscix and pipeline programs, while also recording capital-structure events such as convertible-note settlement and material collaboration agreements involving the Technosphere platform.
The filing record also includes acquisition-related disclosures for the completed scPharma transaction, including acquired-business financial statements and pro forma combined financial information. MannKind proxy materials address annual meeting matters, executive compensation and equity-award information, and other governance subjects tied to its common stock.
MannKind Corp reported new equity awards for EVP Technical Operations Sanjay R. Singh. He received 221,000 performance-based restricted stock units, each tied to one common share, that vest on January 15, 2029 with payout ranging from 0% to 300% of target based on relative total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 through December 31, 2028. He was also granted options on 217,000 shares at an exercise price of $2.44 per share, vesting 25% on March 23, 2027 and the remainder in equal quarterly installments through 2031, expiring March 23, 2036. These are compensation-related grants, not open-market trades.
MannKind Corporation’s Chief Medical Officer, Ajay Ahuja, reported new equity awards. He received 221,000 performance-based restricted stock units, each representing a right to one share of common stock. These units vest on January 15, 2029, with the actual payout ranging from 0% to 300% of the target based on MannKind’s total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 through December 31, 2028.
He was also granted options on 217,000 shares of common stock at an exercise price of $2.44 per share. These options vest 25% on March 23, 2027, with the remaining 75% vesting in 1/16th increments quarterly, and expire on March 23, 2036. All positions are held directly and reflect compensation awards rather than market purchases or sales.
MannKind Corp granted Chief People & Workplace Officer Stuart A. Tross new equity awards. He received 221,000 performance-based restricted stock units, each representing the right to one share of common stock. These units vest on January 15, 2029, with the payout from 0% to 300% of target based on MannKind’s total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 through December 31, 2028.
He was also granted 217,000 stock options with a $2.44 exercise price, expiring on March 23, 2036. These options vest 25% on March 23, 2027, with the remaining 75% vesting in equal quarterly installments over four years.
MannKind Corp EVP and General Counsel David Thomson reported equity awards, not open-market trades. He received 221,000 performance-based restricted stock units, each representing a contingent right to one share of common stock.
The performance units vest on January 15, 2029, with payout tied to MannKind’s total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 to December 31, 2028. Payout ranges from 0% to 300% of the 221,000-target based on percentile rankings.
Thomson was also granted stock options for 217,000 shares at an exercise price of $2.44 per share, vesting 25% on March 23, 2027 and then 1/16 quarterly through March 23, 2031.
MannKind Corp CEO Michael Castagna purchased 100,000 shares of common stock in an open-market transaction at a weighted average price of $2.59 per share on March 10, 2026. Following this purchase, he directly owns 2,575,911 shares. An additional 1,500 shares are held indirectly through his spouse.
MannKind Corp director Shannon James Samuel acquired 12,000 shares of common stock at a price of $3.27 per share. The acquisition was made through the company’s Market Price Stock Purchase Plan, which was approved by the Board of Directors on March 1, 2026.
Following this grant or award acquisition, Samuel’s direct holdings increased to 64,635 shares of MannKind common stock. This transaction reflects participation in a board-approved stock purchase plan rather than an open-market trading decision.
MannKind Corp director Anthony C. Hooper acquired 35,000 shares of common stock on March 1, 2026 at a price of $3.27 per share. The shares were purchased through the company’s Market Price Stock Purchase Plan, which was approved by the board on that date. Following this transaction, Hooper directly owns 236,153 MannKind shares.
MannKind Corp's Chief Financial Officer Christopher B. Prentiss acquired additional company stock through a board-approved purchase plan. On March 1, 2026, he obtained 5,000 shares of common stock at $3.27 per share under the Market Price Stock Purchase Plan. Following this transaction, he directly owned 348,854 shares of MannKind common stock.
MannKind Corp Chief Executive Officer Michael Castagna reported multiple share and option acquisitions. On March 1, 2026, he acquired 15,290 shares of common stock at $3.27 per share through the company’s Market Price Stock Purchase Plan, which was approved by the board.
Following this, his direct common stock holdings rose to 2,475,911 shares. On February 26, 2026, performance milestones were reached for stock options originally granted in 2016 and 2017, leading to partial vesting of options covering 50,000, 57,750, and 37,525 shares, increasing his directly held option awards.
MannKind Corp director Steven B. Binder reported the vesting of performance-based stock options. On February 26, 2026, a defined performance milestone was achieved under an option originally granted on August 24, 2017, resulting in a grant-credited acquisition of 45,025 employee stock options at an exercise price of $0.00 per option.